mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic endometrial cancer

• New Approvals
• New Drug Applications

FDA Approves Dostarlimab-gxly for Endometrial Cancer With dMMR or MSI-H Mutation

On July 31, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) for primary advanced or recurrent endometrial…